Initiation of SGLT2i in CKD: how, when and who?
Video navigation menu
How to identify patients who are elibible for treatment with SGLT2i 00:04
When to start therapy with SGLT2i 02:54
Who should prescribe SGLT2i? 04:56
Take home messages 08:28
In which patients with CKD would you start SGLT2i therapy?
- A. Only in patients who also have diabetes
- B. Only in patients who also have diabetes or heart failure
- C. In patients with albuminuria >200 mg/g, or heart failure, or diabetes
Educational information
David Cherney, MD, PhD, Roberto Pecoits-Filho, MD, PhD, and Magdalena Madero, MD were discussants at the EBAC-accredited symposium "Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?" held during the WCN 2023 in Bangkok, Thailand.
Faculty
- David Cherney, MD, PhD is a nephrologist and Associate Professor in the Department of Medicine at the University of Toronto. He is also a Clinician Scientist and director of the Renal Physiology Laboratory at the University Health Network and Mount Sinai Hospitals.
- Roberto Pecoits-Filho, MD, PhD is a Professor of Nephrology at the School of Medicine, Catholic University of Paraná State in Brazil and a Senior Research Scientist at the Arbor Research Collaborative for Health in Ann Arbor, MI, USA.
- Magdalena Madero, MD is Chief of Nephrology at the National Heart Institute in Mexico City.
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant received from Boehringer Ingelheim and Lilly Alliance.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: